The global scleroderma therapeutics market size is accounted at USD 2.74 billion in 2025 and is forecasted to hit around USD 4.28 billion by 2034, representing a CAGR of 5.07% from 2025 to 2034. The North America market size was estimated at USD 1.23 billion in 2024 and is expanding at a CAGR of 5.13% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Scleroderma Therapeutics Industry Impact
5.2. COVID-19 - Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Scleroderma Therapeutics Market Revenue and Volume, By Drug Class
8.1.1 Immunosuppressors
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Phosphodiesterase 5 inhibitors – PHA
8.1.2.1. Market Revenue and Volume Forecast
8.1.3 Endothelin Receptor Antagonists
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Prostacyclin Analogues
8.1.4.1. Market Revenue and Volume Forecast
8.1.5. Calcium Channel Blockers
8.1.5.1. Market Revenue and Volume Forecast
8.1.6. Analgesics
8.1.6.1. Market Revenue and Volume Forecast
8.1.7. Others
8.1.7.1. Market Revenue and Volume Forecast
9.1. Scleroderma Therapeutics Market Revenue and Volume, By Indication
9.1.1. Systemic Scleroderma
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Morphea
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Linear
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Localized Scleroderma
9.1.4.1. Market Revenue and Volume Forecast
9.1.5. Diffuse Systemic Sclerosis
9.1.5.1. Market Revenue and Volume Forecast
9.1.6. Limited Cutaneous Systemic Sclerosis Syndrome
9.1.6.1. Market Revenue and Volume Forecast
10.1. North America
10.1.1. Market Revenue and Volume Forecast, By Drug Class
10.1.2. Market Revenue and Volume Forecast, By Indication
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, By Drug Class
10.1.3.2. Market Revenue and Volume Forecast, By Indication
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, By Drug Class
10.1.4.2. Market Revenue and Volume Forecast, By Indication
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, By Drug Class
10.2.2. Market Revenue and Volume Forecast, By Indication
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, By Drug Class
10.2.3.2. Market Revenue and Volume Forecast, By Indication
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, By Drug Class
10.2.4.2. Market Revenue and Volume Forecast, By Indication
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, By Drug Class
10.2.5.2. Market Revenue and Volume Forecast, By Indication
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, By Drug Class
10.2.6.2. Market Revenue and Volume Forecast, By Indication
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, By Drug Class
10.3.2. Market Revenue and Volume Forecast, By Indication
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, By Drug Class
10.3.3.2. Market Revenue and Volume Forecast, By Indication
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, By Drug Class
10.3.4.2. Market Revenue and Volume Forecast, By Indication
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, By Drug Class
10.3.5.2. Market Revenue and Volume Forecast, By Indication
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, By Drug Class
10.3.6.2. Market Revenue and Volume Forecast, By Indication
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, By Drug Class
10.4.2. Market Revenue and Volume Forecast, By Indication
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, By Drug Class
10.4.3.2. Market Revenue and Volume Forecast, By Indication
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, By Drug Class
10.4.4.2. Market Revenue and Volume Forecast, By Indication
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, By Drug Class
10.4.5.2. Market Revenue and Volume Forecast, By Indication
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, By Drug Class
10.4.6.2. Market Revenue and Volume Forecast, By Indication
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, By Drug Class
10.5.2. Market Revenue and Volume Forecast, By Indication
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, By Drug Class
10.5.3.2. Market Revenue and Volume Forecast, By Indication
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, By Drug Class
10.5.4.2. Market Revenue and Volume Forecast, By Indication
11.1. Scleroderma Therapeutics Market Companies
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. F. Hoffmann-La Roche AG
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Bristol-Myers Squibb Company
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Corbus Pharmaceuticals Holdings, Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Calliditas Therapeutics AB.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Celgene Corporation
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Argentis Pharmaceuticals
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. LLC
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Emerald Health Pharmaceutical
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Kadmon Holdings
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample